Skip Navigation Links
     
ABSTRACT SU RIVISTE
  • Squillace N, Ricci E, Menzaghi B, Migliorino G, De Socio G, Passerini S, Martinelli C, Mameli M, Maggi P, Falasca K, Cordier L, Celesia B, Salomoni E, Di Biagio A, Pellicano G, Bonfanti P.
    Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and hepatic safety: A new paradigm?
    Journal of the International AIDS Society 2018 21 Supplement 8 (145)
  • Menzaghi B, Magni C, Nicolini L.A, Cenderello G, Fiore V, Gussio M, Gulminetti R, Vichi F, Bonfanti P.
    HCC development in HCV patients after DAA: The experience of the scolta project.
    Topics in Antiviral Medicine 2017 25:1 Supplement 1 (225s-)
  • Menzaghi B, Ricci E, Magni C, Parruti G, Nicolini L, Cenderello G, Peruzzu F, Gussio M, Gulminetti R, Bonfanti P.
    Current treatment options for hepatitis C virus/human immunodeficiency virus patients: The experience of the scolta project.
    Journal of Hepatology 2017 66:1 Supplement 1 (S291-)
  • Nicolini L.A, Ricci E, Menzaghi B, Madeddu G, Maggi P, Di Biagio A, Bonfanti P, Passerini S, Magni C.F, Salomoni E, Maurizio C.B, Patacca A, Squillace N, Vichi F, Falasca K, Gulminetti R, Grosso C, Quirino T.
    Regression of liver fibrosis following Sustained Viral response (SVR) with Interferon(IFN)-free HCV treatment.
    Hepatology 2016 64:1 Supplement 1 (967A-968A)
  • Madeddu G, Ricci E, Gulminetti R, Paola B, Squillace N, De Socio G, Menzaghi B, Giancarlo O, Molteni C, Rusconi S, Celesia B.M, Bellacosa C, Di Biagio A, Pellicanò G, Martinelli C, Carenzi L, Valsecchi L, Calza L, Falasca K, Vichi F, Penco G, Bonfanti P.
    Dolutegravir tolerability in clinical practice: Results from the SCOLTA color.
    Journal of the International AIDS Society 2016 19 Supplement 7 (168-169)
  • Squillace N, Bonfanti P, Ricci E, Calza L, Celesia B.M, Martinelli C, Vichi F, Cordier L, Carenzi L, Franzetti M, De Socio G, Peruzzu F, Orofino G, Bellacosa C, Di Biagio A, Gori A, Quirino T.
    Adverse events occurring after introduction of EVG/COBI/ FTC/TDF: Data from the Surveillance Cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) cohort.
    Journal of the International AIDS Society 2016 19 Supplement 7 (170-171)
  • De Socio GV, Ricci E, Quirino T, Schillaci G, Martinelli C, Parruti G, Marconi P, Franzetti M, Vichi F, Penco G, Madeddu G, Orofino G, Vitiello P, Menzaghi B, Bonfanti P. for the CISAI Study Group
    Waist circumference and body mass index in HIV infection.
    Infection 2010; 38 (Suppl. I): 81
  • Madeddu G, Soddu V, Ricci E, Quirino T, Menzaghi B, Bellacosa C, Grosso C, Melzi S, Valsecchi L, Franzetti M, Vichi F, Penco G, Di Biagio A, Pellicanò G, Corsico L, De Socio GV, Mazzotta E, Parruti G, Guastavigna M, Orofino G, Mura MS, Bonfanti P.
    Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study.
    J Int AIDS Soc 2010; 13 (S4):P111.
  • De Socio GV, Martinelli C, Ricci E, Orofino G, Valsecchi L, Vitiello P, Martinelli L, Quirino T, Maggi P, Bonfanti P.
    Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES Study.
    EACS 2009 11-14 November, 2009, Cologne, Germeny. HIV Med 2009; 10 (S2): PS11/4.
  • De Socio GV, Martinelli C, Ricci E, Schillaci G, Pucci G, Mastronardi V, Marinoni M, Magni C, Carenzi L.
    Attenuated diurnal blood pressure rhythm in naïve HIV infected patients. Results from the HERMES Study.
    ICAR May 24-26, 2009, Milan, Italy. Infection 2009; 37 (S2): CO 15.
  • Sozio F, Soddu V, De Socio G, Marconi P, Dalessandro M, Madeddu G, Bonfanti P, Mazzotta E, Vecchiet J, Celesia M, Pellicanò G, Di Masi F, Martinelli C, Vitiello P, Nigro L, Manzoli L, Parruti G.
    48 week efficacy of first line antiretroviral treatments for HIV infection in 1998 and 2006: preliminary results of a multicentric investigation.
    ICAR May 24-26, 2009, Milan, Italy. Infection 2009; 37 (S2): CO 01.
  • Bonfanti P, Ricci E, Orofino G, Martinelli C, Franzetti M, De Socio G, Marconi P, Madeddu G., Vichi F, Vitiello P, Valsecchi L, Penco G, Quirino T.
    Metabolic syndrome in HV-positive naive patients: the HERMES study. 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.
    London, UK, 6-8 November 2008; Abstract P-50, Antiviral Therapy 2008; 13(S4): A58.
  • Quirino T, Ricci E, Giuntini R, Martinelli C, Carradori S, Vichi F, Gianelli E, Madeddu G, Menzaghi B, De Socio G, Orofino G, Palvarini L, Penco G, Rosella E, Marconi P, Grosso C, Pellicanò G, Bonfanti P, for CISAI Study Group.
    Long term efficacy of boosted and unboosted atazanavir containing regimens: results from the SCOLTA Project.
    Ninth International Congress on Drug Therapy in HIV infection, 9-13 November 2008, Glasgow. J Int AIDS Soc 2008; 11(suppl 1): P74.
  • Sozio F, Soddu V, De Socio G, D’Alessandro m, Polilli E, Madeddu G, Bonfanti P, Mazzotta E, Vecchiet J, Mura MS, Quirino T, Manzoli L, Parruti G.
    Comparison of the efficacy at 48 weeks of first line antiretroviral treatment for HIV infection in 1998n and 2006: a multicentric investigation.
    J Int AIDS Soc 2008; 11 (Suppl I): P19
  • Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Capra A, Citterio F, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G.
    Prevalence of the Metabolic Syndrome in HIV Patients.
    High Blood Press Cardiovascular Prev 2007; 14 (3): 145
  • Bonfanti P, Ricci E, Rusconi S, Martinelli C, Carradori S, Magnani C, Cristina G, De Socio G, Parruti G, Orofino G, Migliorini D, QuirinoT.
    Incidence of adverse reactions and reasons of treatment discontinuation in patients treated with Lopinavir/r in the SCOLTA Project cohort.
    Antiviral Therapy 2006; 11: L65
  • Bonfanti P, Facchetti R, Melzi S, Bombelli M, Cordier L, Franzetti M, Polo Friz H, Sfara C, Quirino T, Sega R.
    Metabolic Syndrome and HIV: comparison with the prevalence in the general population (SIMONE vs. PAMELA).
    Antiviral Therapy 2005; 10: L23
  • Bonfanti P, Ricci E, Landonio S, Franzetti M, Melzi S, Grosso C, Pusterla L, Carradori S, Martinelli C, Giustini R, Penco G, Miccolis S, Cordier L, Quirino T.
    Prevalenza della Sindrome Metabolica in una popolazione di HIV-positivi: lo studio SIM1.
    Giorn It Mal Inf 2005; 11: (S1): S147
  • Bonfanti P, Quirino T, Ricci E, Magnani C, Martinelli C, Cristina G, Migliorini D, Orofino G, Landonio S, Gulisano C, Carradori S, Madeddu G, Sfara C, Miccolis S, Vigevani GM.
    “Progetto Scolta: un metodo di farmacovigilanza sui farmaci antiretrovirali”.
    Giorn It Mal Inf 2003; 9: (S1): 199
  • Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, Landonio S, Vulpio L, Faggion I, Carrabba M, Vigevani GM.
    “Osteopenia e osteoporosi in pazienti con infezione da HIV”
    Giorn It Mal Inf 2003; 9: (S1): 200
  • Quirino T, Bongiovanni M, Ricci E, Bonfanti P, Chebat E, Martinelli C, Valsecchi L, Carradori S, Landonio S, Bini T, Gabbati A, Giuntini R, Gulisano C, Vigevani GM.
    “ Subcinical hypothiroidism in HIV positive patients: is it iatrogenic or HIV related”
    Antivir Ther 2003; 8: L 91
  • Quirino T, Bonfanti P, Faggion I, Ricci E, Martinelli C, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Landonio S, gabbati A, Vigevani GM.
    “Glucose metabolism abnormalities associated with highly active antiretroviral therapy: a cohort study.”
    Antivir Ther 2002; 7: L25
  • Quirino T, Bonfanti P, Chebat E, Faggion I, Martinelli C, Giuntini R, Valsecchi L, Carradori S, Landonio S, Gabbuti A, Gulisano C, Vigevani GM.
    “Thyroid abnormalities in patients receiving highly active antiretroviral therapy”
    Antivir Ther 2002; 7: L62
  • Bonfanti P, Quirino T, Landonio S, Faggion I, Parazzini F, Vigevani GM.
    “The SCOLTA project: an on-line Italian post-marketing surveillance method for reporting adverse reactions to antiretrovirals drugs.”
    Antivir Ther 2002; 7: L64.
  • Bonfanti P, Quirino T, Faggion I, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Gabbuti A, Cinelli R, Martinelli C, Landonio S, Parazzini F, Vigevani GM
    “Reasons for protease inhibitor discontinuation in a selected cohort of HIV patients”
    Antivir Ther 2001; 6 (S4): 30
  • Quirino T, Bonfanti P, Faggion I, Ricci E, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Miccolis S, Magnani C, Landonio S, Gabbuti A, Cinelli R, Parazzini F, Vigevani GM
    “Risk factors for hepatotoxixity in patients treated with highly active antiretroviral therapy: a cohort study”
    Antivir Ther 2001; 6 (S4): 13
  • Martinelli C, Giuntini R, Landonio S, Quirino T, Bonfanti P, Ruffino I, Massi D, Vigevani GM, Leoncini F.
    “Utility of patch testing in Hiv patients with cutaneous adverse reaction to highly active antiretroviral therapy”.
    J Eur Acad Dermatol Venereol 2004; 18 (S2): 424-425
  • Bonfanti P, Niero F, Ricci E, Iemoli E, Valsecchi L, Timillero L, Landonio S, Faggion I, Alessi F, Cinelli R, Parazzini F, Quirino T.
    “HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV infected patients.”
    Antivir Ther 2000; 5 (S5): 51-52
  • Bonfanti P, Ricci E, Landonio S, Faggion I, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Martinelli C, Parazzini F, Quirino T.
    “Adverse events in patients treated with protease inhibitors: a cohort study”.
    Antivir Ther 2000; 5 (S5): 52
  • Bonfanti P, Ricci E, Faggion I, Valsecchi L, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Martinelli C, Parazzini F, Landonio S, Quirino T.
    Role of nucleoside reverse transcriptase inhibitors in causing adverse events in the HAART-treated patients.
    AIDS 2000; 14 (S4): 65-66
CHI SIAMO
Gestisci preferenze cookie
FONDAZIONE A.S.I.A. ONLUS  /  VIA GARIBALDI, 13  /  20090 BUCCINASCO (MI)  /  P.IVA 05087350962
POWERED BY HEALTHROPY
Cookie policy
Privacy policy